The role of phosphodiesterase type-5 inhibitors in Benign Prostatic Hyperplasia, current approaches

Basit Öğe Kaydı
dc.authoridkemahli, eray/0000-0003-1698-8263
dc.contributor.authorKemahli, Eray
dc.contributor.authorGucuk, Adnan
dc.contributor.authorUyeturk, Ugur
dc.date.accessioned2024-09-25T19:56:27Z
dc.date.available2024-09-25T19:56:27Z
dc.date.issued2013
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractBoth benign prostatic hyperplasia (BPH) that manifested with lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are common health problems reducing quality of life in aging males. It has presumed that phosphodiesterase type 5 (PDE5) inhibitors which are primarily used in the treatment of ED may have therapeutic effects on BPH because of possible common pathophysiology between BPH and ED. There are many recent studies relevant to the this issue. Especially, after the FDA approval of tadalafil in the treatment of BPH, it has been entered to our daily practice as monotherapy or in combination with alpha-blocker drugs. PDE5 inhibitors may be preferred as a first line treatment option in patients who suffer both BPH and ED simultaneously, however, it is possible to use in patients with BPH only. Younger patients with low body mass index and with severe LUTS have more benefit with PDE5 inhibitor therapy. Flushing, gastroesophageal reflux, headache, and dyspepsia are the most frequently reported adverse effects of PDE5 inhibitors. These adverse effects are mild to moderate, and require the therapy to be discontinued in a small portion of patients. In this review, it is aimed to evaluate the use of PDE5 inhibitors in the treatment of BPH with the current literatures.en_US
dc.identifier.endpage246en_US
dc.identifier.issn2147-2270
dc.identifier.issue4en_US
dc.identifier.startpage242en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/13308
dc.identifier.volume12en_US
dc.identifier.wosWOS:000219391900005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofUroonkoloji Bulteni-Bulletin of Urooncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectBenign Prostatic Hyperplasiaen_US
dc.subjectLower Urinary Tract Symptomsen_US
dc.subjectPhosphodiesterase Type-5 Inhibitorsen_US
dc.subjectErectile Dysfunctionen_US
dc.titleThe role of phosphodiesterase type-5 inhibitors in Benign Prostatic Hyperplasia, current approachesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu